Surface-modified HK:siRNA nanoplexes with enhanced pharmacokinetics and tumor growth inhibition.

Surface-modified HK:siRNA nanoplexes with enhanced pharmacokinetics and tumor growth inhibition.
复制标题

DOI:
10.1021/bm3018356
复制
发表时间:
2013-03-11
期刊:
影响因子:
6.2
通讯作者:
Mixson, A. James
Mixson, A. James
中科院分区:
化学2区
文献类型:
--
作者:
Chou, Szu-Ting;Leng, Qixin;Scaria, Puthupparampil;Kahn, Jason D.;Tricoli, Lucas J.;Woodle, Martin;Mixson, A. James

文献摘要

参考文献

被引文献

相似文献

我们在这项研究中表征了组氨酸-赖氨酸(HK):用 PEG 和靶向 αvβ3 和 αvβ5 整合素的环状 RGD (cRGD) 配体修饰的 siRNA 纳米复合物的药代动力学和抗肿瘤功效。通过无创成像,与未修饰的 HK:siRNA 纳米复合物相比,全身施用表面修饰的 HK:siRNA 纳米复合物的血液水平高出近 4 倍,肿瘤组织中的积累量高出 40%,荧光素酶活性低 60%。然后,我们确定表面修饰的 HK:siRNA 纳米复合物载体是否更有效地通过靶向 Raf-1 的 siRNA 减少 MDA-MB-435 肿瘤生长。重复全身施用选定的靶向 Raf-1 的表面修饰 HK:siRNA 纳米复合物,显示出比未修饰的 HK:siRNA 纳米复合物对肿瘤生长的抑制作用强 35%,对肿瘤生长的抑制作用比未治疗的小鼠强 60%。 HK:siRNA 纳米复合物的整合素靶向表面修饰观察到改善的血液药代动力学结果和肿瘤定位,与更强的肿瘤生长抑制相关。这项研究表明,通过控制与空间 PEG 层相关的靶向配体表面展示,修饰的 HK: siRNA 纳米复合物有望推动肿瘤学和其他潜在关键疾病的 RNAi 治疗。
We characterized in this study the pharmacokinetics and antitumor efficacy of histidine-lysine (HK):siRNA nanoplexes modified with PEG and a cyclic RGD (cRGD) ligand targeting αvβ3 and αvβ5 integrins. With noninvasive imaging, systemically administered surface-modified HK:siRNA nanoplexes showed nearly 4-fold greater blood levels, 40% higher accumulation in tumor tissue, and 60% lower luciferase activity than unmodified HK:siRNA nanoplexes. We then determined whether the surface-modified HK:siRNA nanoplex carrier was more effective in reducing MDA-MB-435 tumor growth with an siRNA targeting Raf-1. Repeated systemic administration of the selected surface modified HK:siRNA nanoplexes targeting Raf-1 showed 35% greater inhibition of tumor growth than unmodified HK:siRNA nanoplexes and 60% greater inhibition of tumor growth than untreated mice. The improved blood pharmacokinetic results and tumor localization observed with the integrin-targeting surface modification of HK:siRNA nanoplexes correlated with greater tumor growth inhibition. This investigation reveals that through control of targeting ligand surface display in association with a steric PEG layer, modified HK: siRNA nanoplexes show promise to advance RNAi therapeutics in oncology and potentially other critical diseases.
DOI: 10.1371/journal.pone.0009536
发表时间: 2010-03-04
期刊: PloS one
影响因子: 3.7
作者:
Lee MJ;Veiseh O;Bhattarai N;Sun C;Hansen SJ;Ditzler S;Knoblaugh S;Lee D;Ellenbogen R;Zhang M;Olson JM
通讯作者: Olson JM
DOI: 10.1038/nbt.1807
发表时间: 2011-04-01
影响因子: 46.9
作者:
Alvarez-Erviti, Lydia;Seow, Yiqi;Wood, Matthew J. A.
通讯作者: Wood, Matthew J. A.
DOI: 10.1093/nar/gkj439
发表时间: 2006
影响因子: 14.9
作者:
Bartlett DW;Davis ME
通讯作者: Davis ME
DOI: 10.1358/dof.2009.034.09.1413267
发表时间: 2009-09
影响因子: 0.2
作者:
Leng Q;Woodle MC;Lu PY;Mixson AJ
通讯作者: Mixson AJ
DOI: 10.1038/sj.gt.3301351
发表时间: 2001-01-01
期刊: GENE THERAPY
影响因子: 5.1
作者:
Kircheis, R;Wightman, L;Wagner, E
通讯作者: Wagner, E